The DOI matches its Crossref record.
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tofacitinib and baricitinib are efficacious against rheumatoid arthritis and have been approved for its treatment.
“Tofacitinib and baricitinib are efficacious against RA and have been approved for the treatment of RA.”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Lee et al., 2014
In a phase III trial, tofacitinib monotherapy is superior to methotrexate in reducing signs and symptoms of rheumatoid arthritis and inhibiting progression of structural joint damage.
“tofacitinib monotherapy is superior to MTX in reducing signs and symptoms of RA and inhibiting the progression of structural joint damage”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Lee et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 32
- 10.1056/NEJMra040226 · DOI
- 10.1002/acr.21641 · DOI
- 10.1136/ard.2009.126532 · DOI
- 10.1136/ard.2005.035709 · DOI
- 10.1002/art.20568 · DOI
- 10.1136/ard.2009.123919 · DOI
- 10.1016/S0140-6736(08)61000-4 · DOI
- 10.1002/art.21519 · DOI
- Maradit-Kremers H, 2006, J Rheumatol, 33, 248
- 10.1002/art.37711 · DOI
- 10.1136/ard.2010.137703 · DOI
- 10.1186/1476-9255-7-41 · DOI
- 10.1056/NEJMoa1109071 · DOI
- 10.1056/NEJMoa1112072 · DOI
- 10.1016/S0140-6736(12)61424-X · DOI
- 10.7326/0003-4819-159-4-201308200-00006 · DOI
- 10.1002/art.37816 · DOI
- 10.1002/art.1780310302 · DOI
- van der Heijde D, 2000, J Rheumatol, 27, 261
- 10.1002/art.10181 · DOI
- 10.1002/art.10190 · DOI
- 10.1002/art.30263 · DOI
- 10.1136/ard.2008.101121 · DOI
- 10.1001/archinte.159.21.2542 · DOI
- 10.1093/rheumatology/39.6.655 · DOI
- 10.1136/ard.2008.105197 · DOI · Paper page
- 10.1056/NEJM200011303432201 · DOI
- 10.1016/S0140-6736(98)08513-4 · DOI
- 10.1056/NEJM199507203330301 · DOI
- 10.1002/art.10308 · DOI
- 10.1136/annrheumdis-2012-202442 · DOI
- 10.1136/annrheumdis-2012-eular.595 · DOI
Cited by
Sorted by citations
Immunopathogenesis of Rheumatoid Arthritis
Firestein, G. S., & McInnes, I. B. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.006 · Cited by 1,301
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Winthrop, K. L., Silverfield, J., Racewicz, A., Neal, J., Lee, E. B., Hrycaj, P., Gomez-Reino, J., Soma, K., Mebus, C., Wilkinson, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207191 · Cited by 196
Self-citation
Metadata
- Authors
- Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., Zwillich, S. H., & van Vollenhoven, R. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-06-19
- Volume
- 370
- Issue
- 25
- Pages
- 2377-2386
- ISSN
- 0028-4793
- 1533-4406
- Cited by
- 711
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
